Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dimerix HIT Assay to Understand Receptor Interactions Applied to Kinase Targets

Published: Friday, May 31, 2013
Last Updated: Thursday, May 30, 2013
Bookmark and Share
Better understanding of receptor signalling, including effects arising from their functional interaction in heteromeric complexes, will progress drug development. Dimerix’s HIT assay is used to understand kinase heteromer signalling pathways.

Patents have now been granted for Dimerix’s Heteromer Investigation Technology (HIT) assay in the US, Europe, China and Australia, with applications pending in other jurisdictions.  Dimerix’s HIT assay enables a ligand responsive interrogation of a wide range of signalling pathways that can be triggered by a complex of at least two receptors (or proteins).  The assay can be utilised in high-throughput screening to obtain novel hits against the heteromer target and its components, or employed to better profile existing leads for signalling elicited through heteromer formation.  The broad application of Dimerix’s technology enables it to be licensed for a range of proximity-based reporter systems enabling optimal information and outcomes.

Most recently, an application of Dimerix’s assay to kinase heteromers has been reported.  A/Prof Kevin Pfleger, co-inventor of Dimerix’s assay technology, is senior author of a paper entitled ‘Profiling Epidermal Growth Factor Receptor and Heregulin Receptor Heteromerization Using Receptor Tyrosine Kinase Heteromer Investigation Technology’ published 20 May 2013 in PLOS ONE.

The study demonstrates the use of Dimerix’s HIT assay to investigate the heteromeric complexes formed by EGFR and HER3 receptors, and the effect on the Grb2 signalling pathway.  The data show that heteromerization of the receptors is required for HER3 to interact with Grb2, including evidence that this occurs via a transactivation mechanism.

Why is this important?  These kinase receptors are known to be involved in various human cancers.  Better understanding of receptor signalling, including effects arising from their functional interaction in heteromeric complexes, will progress drug development.  Indeed, the importance of EGFR-HER3 heteromerization has been demonstrated by other studies showing a beneficial effect of dual-action antibodies targeting both receptors. 

Dimerix’s assay not only provides a useful tool for interrogating heteromer signalling, but can also be used for high-throughput screening to identify hits against the heteromer as well as respective monomers.  In collaborative work with partners, Dimerix has enabled profiling and screening activities encompassing a range of proteins and signalling pathways.  Dimerix has strong expertise in the area of GPCRs and their various G-protein or beta-arrestin signalling pathways, including GPCR deorphanisation.

Dimerix’s internal research has used its assay in a core research program to develop an improved therapy for reduction of proteinuria in chronic kidney disease. Proteinuria is an indicator of ongoing kidney damage.

More information is available on Dimerix’s website: www.dimerix.com. To see a schematic of Dimerix’s assay for different reporter systems, please go to the Dimerix Platform section of our website.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Identified Compound Stops Cells Making Ribosomes
From study in yeast, researchers have identifed a compound that interferes with the assembly of ribosomes.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!